TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Acurx Pharmaceuticals ( (ACXP) ) just unveiled an update.
On September 16, 2025, Acurx Pharmaceuticals‘ stockholders approved an amendment to increase the company’s authorized common stock shares from 200,000,000 to 250,000,000. The amendment was filed with the Secretary of State of Delaware on September 22, 2025, and took immediate effect, potentially impacting the company’s financial flexibility and market operations.
The most recent analyst rating on (ACXP) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Acurx Pharmaceuticals stock, see the ACXP Stock Forecast page.
Spark’s Take on ACXP Stock
According to Spark, TipRanks’ AI Analyst, ACXP is a Underperform.
Acurx Pharmaceuticals’ score reflects the challenges of an early-stage biotech, including lack of revenue and ongoing losses, balanced by strong potential in clinical advancements and regulatory support. Technical indicators suggest weak momentum, and valuation is hindered by financial fundamentals.
To see Spark’s full report on ACXP stock, click here.
More about Acurx Pharmaceuticals
Average Trading Volume: 75,888
Technical Sentiment Signal: Sell
Current Market Cap: $6.5M
For detailed information about ACXP stock, go to TipRanks’ Stock Analysis page.